Compare Stocks: IPSC, SLN, SNDX, and VOR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IPSC Century Therapeutics	$1.42 -2.7%	$1.79	$0.44 ▼ $3.04	$257.12M	1.67	1.25 million shs	493,653 shs
SLN Silence Therapeutics	$19.78 +0.6%	$12.90	$4.19 ▼ $19.87	$1.19B	1.45	1.09 million shs	4.65 million shs
SNDX Syndax Pharmaceuticals	$13.22 -1.3%	$17.82	$12.80 ▼ $25.59	$1.17B	0.42	1.69 million shs	1.99 million shs
VOR Vor Biopharma	$18.33 +0.4%	$21.13	$6.50 ▼ $28.66	$1.08B	1.78	1.05 million shs	470,337 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IPSC Century Therapeutics	0.00%	+6.57%	-12.57%	-30.14%	+152.90%
SLN Silence Therapeutics	0.00%	+126.61%	+75.94%	+62.97%	+169.45%
SNDX Syndax Pharmaceuticals	0.00%	+3.88%	-26.37%	-34.70%	-0.96%
VOR Vor Biopharma	0.00%	+1.28%	-1.40%	-6.07%	-32.84%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IPSC Century Therapeutics	$1.42 -2.7%	$1.79	$0.44 ▼ $3.04	$257.12M	1.67	1.25 million shs	493,653 shs
SLN Silence Therapeutics	$19.78 +0.6%	$12.90	$4.19 ▼ $19.87	$1.19B	1.45	1.09 million shs	4.65 million shs
SNDX Syndax Pharmaceuticals	$13.22 -1.3%	$17.82	$12.80 ▼ $25.59	$1.17B	0.42	1.69 million shs	1.99 million shs
VOR Vor Biopharma	$18.33 +0.4%	$21.13	$6.50 ▼ $28.66	$1.08B	1.78	1.05 million shs	470,337 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IPSC Century Therapeutics	0.00%	+6.57%	-12.57%	-30.14%	+152.90%
SLN Silence Therapeutics	0.00%	+126.61%	+75.94%	+62.97%	+169.45%
SNDX Syndax Pharmaceuticals	0.00%	+3.88%	-26.37%	-34.70%	-0.96%
VOR Vor Biopharma	0.00%	+1.28%	-1.40%	-6.07%	-32.84%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IPSC Century Therapeutics	2.43	Hold	$4.75	234.51% Upside
SLN Silence Therapeutics	2.14	Hold	$24.00	21.33% Upside
SNDX Syndax Pharmaceuticals	2.82	Moderate Buy	$41.80	216.19% Upside
VOR Vor Biopharma	2.90	Moderate Buy	$38.00	107.31% Upside

Current Analyst Ratings Breakdown

Latest IPSC, SLN, SNDX, and VOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/21/2026	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
10/21/2026	SLN Silence Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Neutral	$75.00 ➝ $20.00
10/21/2026	VOR Vor Biopharma	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/19/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/19/2026	SLN Silence Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Hold	$20.00
10/19/2026	SLN Silence Therapeutics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Hold
10/15/2026	SLN Silence Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	VOR Vor Biopharma	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/13/2026	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$38.00
10/2/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/1/2026	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy

(Data available from 10/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IPSC Century Therapeutics	$109.16M	2.36	$0.01 per share	109.78	$1.82 per share	0.78
SLN Silence Therapeutics	$560K	2,126.70	N/A	N/A	$1.32 per share	14.98
SNDX Syndax Pharmaceuticals	$172.35M	6.80	N/A	N/A	$0.74 per share	17.86
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IPSC Century Therapeutics	-$9.58M	-$0.93	N/A	N/A	N/A	N/A	-49.51%	-38.09%	11/12/2026 (Estimated)
SLN Silence Therapeutics	-$88.61M	-$1.28	N/A	N/A	N/A	-8,943.86%	-106.94%	-47.99%	11/5/2026 (Estimated)
SNDX Syndax Pharmaceuticals	-$285.42M	-$2.51	N/A	N/A	N/A	-87.52%	-372.94%	-39.11%	11/2/2026 (Estimated)
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest IPSC, SLN, SNDX, and VOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	IPSC Century Therapeutics	-$0.12	N/A	N/A	N/A	$1.63 million	N/A
11/5/2026	Q3 2026	SLN Silence Therapeutics	-$0.1129	N/A	N/A	N/A	$0.11 million	N/A
11/2/2026	Q3 2026	SNDX Syndax Pharmaceuticals	-$0.4848	N/A	N/A	N/A	$81.91 million	N/A
8/12/2026	Q2 2026	IPSC Century Therapeutics	-$0.11	-$0.17	-$0.06	-$0.17	$2.17 million	N/A
8/11/2026	Q2 2026	VOR Vor Biopharma	-$0.69	-$0.80	-$0.11	-$1.16	N/A	N/A
8/10/2026	Q2 2026	SLN Silence Therapeutics	-$0.1387	-$0.26	-$0.1213	-$0.27	$1.13 million	N/A
8/4/2026	Q2 2026	SNDX Syndax Pharmaceuticals	-$0.4477	-$0.55	-$0.1023	-$0.55	$79.36 million	$72.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IPSC Century Therapeutics	N/A	8.28	8.28
SLN Silence Therapeutics	N/A	7.42	7.42
SNDX Syndax Pharmaceuticals	38.95	6.77	6.44
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IPSC Century Therapeutics	50.20%
SLN Silence Therapeutics	98.73%
SNDX Syndax Pharmaceuticals	N/A
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
IPSC Century Therapeutics	2.40%
SLN Silence Therapeutics	3.00%
SNDX Syndax Pharmaceuticals	4.80%
VOR Vor Biopharma	0.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IPSC Century Therapeutics	78	181.07 million	176.73 million	Optionable
SLN Silence Therapeutics	88	60.21 million	58.40 million	Optionable
SNDX Syndax Pharmaceuticals	298	88.61 million	84.36 million	Optionable
VOR Vor Biopharma	76	59.16 million	59.00 million	Optionable

IPSC, SLN, SNDX, and VOR Headlines

Recent News About These Companies

Vor Bio Announces Final Two-Year Results From Phase 3 TELIGAN Trial Evaluating Telitacicept In Adults With IgA Nephropathy

October 23 at 8:10 AM | marketscreener.comM

Vor Biopharma Inc. (NASDAQ:VOR) Stock Now Rated "Moderate Buy" by Wall Street Analysts

October 23 at 2:44 AM | americanbankingnews.com

Vor Biopharma Inc. (VOR) - What Are Investment Firms Thinking About This Stock?

October 23 at 2:43 AM | marketbeat.com

William Blair Begins Coverage on Vor Biopharma (NASDAQ:VOR)

October 23 at 1:36 AM | americanbankingnews.com

Vor Bio says its experimental drug slowed loss of kidney function in late-stage study

October 22, 2026 | reuters.com

Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy

October 22, 2026 | globenewswire.com

William Blair initiates coverage of Vor Biopharma at outperform

October 21, 2026 | msn.com

William Blair Initiates Vor Biopharma at Outperform

October 21, 2026 | marketscreener.comM

Vor Biopharma (NASDAQ:VOR) Now Covered by Analysts at William Blair

October 21, 2026 | marketbeat.com

Wells Fargo Keeps Their Buy Rating on Vor Biopharma (VOR)

October 19, 2026 | theglobeandmail.com

Vor Biopharma (NASDAQ:VOR) Upgraded to Strong-Buy at Citigroup

October 17, 2026 | marketbeat.com

Vor Biopharma (NASDAQ:VOR) Shares Climb 7.2% - Time to Buy?

October 15, 2026 | marketbeat.com

Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw Focus

October 9, 2026 | uk.finance.yahoo.com

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 5, 2026 | globenewswire.com

Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)

October 4, 2026 | finance.yahoo.com

Vor Biopharma (NASDAQ:VOR) Stock Jumps 5.3% - Here's What Happened

September 30, 2026 | marketbeat.com

Vor Biopharma: Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

September 29, 2026 | finanznachrichten.de

Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

September 29, 2026 | marketscreener.comM

Vor Biopharma en hausse après la publication de résultats encourageants concernant un médicament contre les maladies auto-immunes

September 29, 2026 | boursorama.comB

Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

September 29, 2026 | globenewswire.com

Vor Biopharma (VOR) Gets a Buy from Stifel Nicolaus

September 29, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC, SLN, SNDX, and VOR Company Descriptions

Century Therapeutics NASDAQ:IPSC

$1.42 -0.04 (-2.74%)

Closing price 04:00 PM Eastern

Extended Trading

$1.42 0.00 (-0.35%)

As of 06:59 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Silence Therapeutics NASDAQ:SLN

$19.78 +0.11 (+0.56%)

Closing price 04:00 PM Eastern

Extended Trading

$19.70 -0.08 (-0.38%)

As of 07:30 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Syndax Pharmaceuticals NASDAQ:SNDX

$13.22 -0.18 (-1.34%)

As of 04:00 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Vor Biopharma NASDAQ:VOR

$18.33 +0.07 (+0.38%)

Closing price 04:00 PM Eastern

Extended Trading

$18.32 0.00 (-0.03%)

As of 07:30 PM Eastern

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IPSC, SLN, SNDX, and VOR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPSC, SLN, SNDX, and VOR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPSC, SLN, SNDX, and VOR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC, SLN, SNDX, and VOR Company Descriptions

Century Therapeutics NASDAQ:IPSC

Silence Therapeutics NASDAQ:SLN

Syndax Pharmaceuticals NASDAQ:SNDX

Vor Biopharma NASDAQ:VOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IPSC, SLN, SNDX, and VOR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPSC, SLN, SNDX, and VOR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPSC, SLN, SNDX, and VOR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC, SLN, SNDX, and VOR Company Descriptions

Century Therapeutics NASDAQ:IPSC

Silence Therapeutics NASDAQ:SLN

Syndax Pharmaceuticals NASDAQ:SNDX

Vor Biopharma NASDAQ:VOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools